PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: FTPB (French Technology Press Bureau)

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

IN CELL ART and Sanofi Pasteur Enter into Research Collaboration Agreement - IN CELL ART, a biotechnology company involved in macromolecular drug (siRNA, DNA, proteins) delivery systems, has announced that the company has entered into a research collaboration agreement with Sanofi Pasteur
IN CELL ART and Sanofi Pasteur Enter into Research Collaboration Agreement

 

NewswireToday - /newswire/ - London, United Kingdom, 2008/09/09 - IN CELL ART, a biotechnology company involved in macromolecular drug (siRNA, DNA, proteins) delivery systems, has announced that the company has entered into a research collaboration agreement with Sanofi Pasteur.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

IN CELL ART, announced that the company has entered into a research collaboration agreement with Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, to evaluate IN CELL ART nanocarriers’ technologies in the context of Sanofi Pasteur’s vaccines programme. Convincing results arising from such studies should lead to the continuation of IN CELL ART nanocarriers’ evaluation in Sanofi Pasteur’s new vaccines development.

IN CELL ART offers a range of biotechnology development services. The French company has expertise in antibody generation using genetic immunisation, allowing for the rapid synthesis of antibodies to any gene-specific antigen. This technology is particularly suitable for screening applications, which lead to the identification of antibodies of therapeutic interest.

IN CELL ART is also pursuing highly promising approaches in the field of DNA-based therapeutic and prophylactic vaccines, with successful studies in animal models of cancers and infectious diseases. IN CELL ART works in partnership with pharmaceutical and biotechnology companies and grants licences for its vaccine formulation.

With ongoing R&D programmes in the fields of oncology, as well as cardiovascular and anti-infectious diseases, IN CELL ART also works closely with companies that are active in the development of RNAi therapeutic products for interference with the expression of targeted disease-associated genes. Besides, IN CELL ART works with companies involved in the development of therapeutic proteins for the improvement of pharmacokinetics. In both these areas, IN CELL ART grants licences for its nanocarriers.

Finally, IN CELL ART is commercializing ICAFectin®441 and ICAFectin®442, which are DNA and siRNA transfection reagents for primary and stem cells.

About IN CELL ART

IN CELL ART (incellart.com), which is headquartered in Nantes (in western France), is a biopharmaceutical company specialising in the preclinical and pharmaceutical development of nanocarriers for macromolecular drugs. Its founder and research team, which includes a Nobel Laureate, have designed new classes of vectors that are organised on a nanometric scale, which enables them to cross the cell barrier efficiently and safely.

IN CELL ART is a privately held company, which was founded in 2005. It is a member of the Atlantic Biotherapies high-tech cluster of biotechnology companies in western France.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: FTPB (French Technology Press Bureau)

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


IN CELL ART and Sanofi Pasteur Enter into Research Collaboration Agreement

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Kate Ambler - UBIFRANCE.fr 
+44(0)20 7235 5330 contact.ftpb[.]ubifrance.fr
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any FTPB (French Technology Press Bureau) securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From FTPB (French Technology Press Bureau) / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Intrinsic Executive Search Ltd

Visit MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)